Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models()

Elevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian cancer (EOC), thus establishing this receptor as a candidate target for the development of novel therapeutics to treat this disease. Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponte, Jose F., Ab, Olga, Lanieri, Leanne, Lee, Jenny, Coccia, Jennifer, Bartle, Laura M., Themeles, Marian, Zhou, Yinghui, Pinkas, Jan, Ruiz-Soto, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126132/
https://www.ncbi.nlm.nih.gov/pubmed/27889646
http://dx.doi.org/10.1016/j.neo.2016.11.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126132/
https://www.ncbi.nlm.nih.gov/pubmed/27889646
http://dx.doi.org/10.1016/j.neo.2016.11.002

Ejemplares similares